Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Revises FY 2003 Financial Targets

NEW YORK, Oct. 7 (GenomeWeb News) - Sequenom yesterday lowered its financial targets for the 2003 fiscal year, predicting total revenues of approximately $30 million for the calendar year and a year-end cash balance of $65 million.

In August, Sequenom CFO Steve Zaniboni told GenomeWeb News' sister publication SNPtech Reporter that the company's overall target revenue for the year was $34 million, with $32 million of that coming from its Systems unit. Yesterday, the company lowered that goal to $30 million, including $28.5 million from the Systems business unit. This amount reflects a growth rate of 15 percent over 2002 Systems business unit revenue of $24.8 million, the company said. 

Sequenom's annual revenue for the 2002 fiscal year was $30.9 million, and $30.7 million for fiscal year 2001.

Sequenom said it is expecting revenues for the third quarter to be approximately $7 million, including around $4 million in MassArray consumable sales. The company said this is a 75 percent increase from the same period last year.

Sequenom also lowered its projected 2003 year-end cash balance to around $65 million, from the $70 million to $75 million it predicted in April when it reported its first-quarter earnings.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.